Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
or

Beam Therapeutics Inc (BEAM)

Beam Therapeutics Inc (BEAM)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
17.64 -1.89 (-9.68%) 04/01/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 17.70 +0.06 (+0.34%) 19:59 ET
Quote Overview for Tue, Apr 1st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
17.55
Day High
19.45
Open 19.45
Previous Close 19.53 19.53
Volume 4,371,100 4,371,100
Avg Vol 2,656,660 2,656,660
Stochastic %K 7.24% 7.24%
Weighted Alpha -47.51 -47.51
5-Day Change -5.58 (-24.05%) -5.58 (-24.05%)
52-Week Range 17.55 - 35.25 17.55 - 35.25
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,948,801
  • Shares Outstanding, K 99,785
  • Annual Sales, $ 63,520 K
  • Annual Income, $ -376,740 K
  • EBIT $ -416 M
  • EBITDA $ -416 M
  • 60-Month Beta 1.91
  • Price/Sales 34.89
  • Price/Cash Flow N/A
  • Price/Book 2.51

Options Overview Details

View History
  • Implied Volatility 78.71% ( -0.33%)
  • Historical Volatility 79.33%
  • IV Percentile 71%
  • IV Rank 61.89%
  • IV High 105.44% on 02/21/25
  • IV Low 35.30% on 05/31/24
  • Put/Call Vol Ratio 1.07
  • Today's Volume 2,019
  • Volume Avg (30-Day) 1,006
  • Put/Call OI Ratio 0.48
  • Today's Open Interest 14,181
  • Open Int (30-Day) 15,178

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -1.11
  • Number of Estimates 5
  • High Estimate -0.94
  • Low Estimate -1.34
  • Prior Year -1.21
  • Growth Rate Est. (year over year) +8.26%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.55 +0.48%
on 04/01/25
Period Open: 26.34
29.05 -39.29%
on 03/07/25
-8.70 (-33.05%)
since 02/28/25
3-Month
17.55 +0.48%
on 04/01/25
Period Open: 24.80
35.25 -49.97%
on 02/18/25
-7.16 (-28.89%)
since 12/31/24
52-Week
17.55 +0.48%
on 04/01/25
Period Open: 32.66
35.25 -49.97%
on 02/18/25
-15.02 (-46.00%)
since 04/01/24

Most Recent Stories

More News
BEAM's IND for BEAM-302 in Genetic Disorder Study Gets FDA Clearance

Beam Therapeutics Inc. BEAM announced that the FDA has cleared the investigational new drug (IND) application to begin clinical studies on its pipeline candidate, BEAM-302, for the treatment of alpha-1...

BEAM : 17.64 (-9.70%)
KRYS : 174.58 (-3.17%)
JAZZ : 124.99 (+0.68%)
DVAX : 12.71 (-2.00%)
Stocks Tumble on Weaker US Consumer Spending and Sticky Price Pressures

The S&P 500 Index ($SPX ) (SPY ) today is down -1.47%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.25%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.89%. June E-mini S&P futures...

APP : 282.70 (+6.69%)
OXM : 59.35 (+1.16%)
WRB : 70.25 (-1.28%)
RKLB : 18.15 (+1.51%)
WYNN : 82.73 (-0.92%)
TXN : 177.99 (-0.95%)
$IUXX : 19,436.42 (+0.82%)
ZNM25 : 111-210 (-0.11%)
HLT : 227.28 (-0.12%)
ESM25 : 5,665.50 (-0.16%)
AMD : 102.78 (+0.04%)
X : 42.17 (-0.21%)
Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration

BEAM : 17.64 (-9.70%)
Beam Therapeutics Announces Pricing of Underwritten Offering

BEAM : 17.64 (-9.70%)
Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation

BEAM : 17.64 (-9.70%)
Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts

BEAM : 17.64 (-9.70%)
Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences

BEAM : 17.64 (-9.70%)
Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference

BEAM : 17.64 (-9.70%)
Is it a Good Idea to Invest in Beam Therapeutics Stock Now?

Beam Therapeutics BEAM is developing its lead pipeline candidate, BEAM-101, a base-editing therapy, in the phase I/II BEACON study for treating sickle cell disease (SCD), an inherited blood disorder.BEAM’s...

BEAM : 17.64 (-9.70%)
VYGR : 3.37 (-0.30%)
CSTL : 19.78 (-1.20%)
HRMY : 32.42 (-2.32%)
Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR

BEAM : 17.64 (-9.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strongest short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Beam Therapeutics Inc. is a biotechnology company. It engages in developing precision genetic medicines through base editing. Beam Therapeutics Inc. is based in Cambridge, Massachusetts.

See More

Key Turning Points

3rd Resistance Point 20.77
2nd Resistance Point 20.11
1st Resistance Point 18.87
Last Price 17.64
1st Support Level 16.97
2nd Support Level 16.31
3rd Support Level 15.07

See More

52-Week High 35.25
Fibonacci 61.8% 28.49
Fibonacci 50% 26.40
Fibonacci 38.2% 24.31
Last Price 17.64
52-Week Low 17.55

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trading Volatility: How to Use IV Rank & Percentile for Smarter Options Strategies